Brief: Lee's Pharma's Unit Got Breakthrough Therapy Designation By NMPA For Oncology Product
09/02/2021 14:41
Feb 9 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* UNIT GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPA FOR
ANTI-PD-L1 MONOCLONAL ANTIBODY, SOCAZOLIMAB
Source text for Eikon: ID:nHKS21GtNf
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA